APO Research
Talk to an analyst

APO RESEARCH · REPORT

Brucellosis Vaccines

Brucellosis vaccine is a vaccine for cattle, sheep and goats used against brucellosis. Currently, there is no vaccine available for humans.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Brucellosis vaccine is a vaccine for cattle, sheep and goats used against brucellosis. Currently, there is no vaccine available for humans.

Selected research

Industry Research

Brucellosis Vaccines Industry Research Report 2026

21 December 2025139 pages

Choose your research edition.

Industry ResearchBrucellosis Vaccines Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Brucellosis Vaccines Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Brucellosis Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Brucellosis Vaccines Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Brucellosis Vaccines Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

Brucellosis vaccine is a vaccine for cattle, sheep and goats used against brucellosis. Currently, there is no vaccine available for humans.

Global Brucellosis Vaccines main players are Jinyu, Colorado Serum, Boehringer Ingelheim, Biogenesis-Bago, etc. Global top four manufacturers hold a share above 35%. China is the largest market, with a share about 30%.

Report Scope

Read the full market overview

This report quantifies the global Brucellosis Vaccines market in terms of revenue (US$ million) and, where applicable, sales volume (M Doses), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/M Doses) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Brucellosis Vaccines Market by Company

Jinyu

Colorado Serum

Boehringer Ingelheim

Biogenesis-Bago

Vetal Company

CZ Veterinaria

SYVA Laboratorios

Indian Immunologicals

Qilu

Tecnovax

Hester Biosciences

Zoetis

Onderstepoort Biological

Instituto Rosenbusch

Ceva Sante Animale

Calier & Biologicos Laverlam

Biovet

Brucellosis Vaccines Segment by Type

S19 Vaccine

RB51 Vaccine Strain

Brucellosis Vaccines Segment by Application

Cattle

Sheep

Others

Brucellosis Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Brucellosis Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Brucellosis Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Brucellosis Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Brucellosis Vaccines manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Brucellosis Vaccines by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Brucellosis Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Brucellosis Vaccines Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Brucellosis Vaccines Sales (M Doses) of Manufacturers (2021-2026) Table 7. Global Brucellosis Vaccines Sales Market Share by Manufacturers (2021-2026) Table 8. Global Brucellosis Vaccines Revenue of Manufacturers (2021-2026) Table 9. Global Brucellosis Vaccines Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Brucellosis Vaccines Average Price (USD/K Doses) of Manufacturers (2021-2026) Table 11. Global Brucellosis Vaccines Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Brucellosis Vaccines, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Brucellosis Vaccines, Product Type & Application Table 14. Global Brucellosis Vaccines Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Brucellosis Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Jinyu Company Information Table 19. Jinyu Business Overview Table 20. Jinyu Brucellosis Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 21. Jinyu Brucellosis Vaccines Product Portfolio Table 22. Jinyu Recent Developments Table 23. Colorado Serum Company Information Table 24. Colorado Serum Business Overview Table 25. Colorado Serum Brucellosis Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 26. Colorado Serum Brucellosis Vaccines Product Portfolio Table 27. Colorado Serum Recent Developments Table 28. Boehringer Ingelheim Company Information Table 29. Boehringer Ingelheim Business Overview Table 30. Boehringer Ingelheim Brucellosis Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 31. Boehringer Ingelheim Brucellosis Vaccines Product Portfolio Table 32. Boehringer Ingelheim Recent Developments Table 33. Biogenesis-Bago Company Information Table 34. Biogenesis-Bago Business Overview Table 35. Biogenesis-Bago Brucellosis Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 36. Biogenesis-Bago Brucellosis Vaccines Product Portfolio Table 37. Biogenesis-Bago Recent Developments Table 38. Vetal Company Company Information Table 39. Vetal Company Business Overview Table 40. Vetal Company Brucellosis Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 41. Vetal Company Brucellosis Vaccines Product Portfolio Table 42. Vetal Company Recent Developments Table 43. CZ Veterinaria Company Information Table 44. CZ Veterinaria Business Overview Table 45. CZ Veterinaria Brucellosis Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 46. CZ Veterinaria Brucellosis Vaccines Product Portfolio Table 47. CZ Veterinaria Recent Developments Table 48. SYVA Laboratorios Company Information Table 49. SYVA Laboratorios Business Overview Table 50. SYVA Laboratorios Brucellosis Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 51. SYVA Laboratorios Brucellosis Vaccines Product Portfolio Table 52. SYVA Laboratorios Recent Developments Table 53. Indian Immunologicals Company Information Table 54. Indian Immunologicals Business Overview Table 55. Indian Immunologicals Brucellosis Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 56. Indian Immunologicals Brucellosis Vaccines Product Portfolio Table 57. Indian Immunologicals Recent Developments Table 58. Qilu Company Information Table 59. Qilu Business Overview Table 60. Qilu Brucellosis Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 61. Qilu Brucellosis Vaccines Product Portfolio Table 62. Qilu Recent Developments Table 63. Tecnovax Company Information Table 64. Tecnovax Business Overview Table 65. Tecnovax Brucellosis Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 66. Tecnovax Brucellosis Vaccines Product Portfolio Table 67. Tecnovax Recent Developments Table 68. Hester Biosciences Company Information Table 69. Hester Biosciences Business Overview Table 70. Hester Biosciences Brucellosis Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 71. Hester Biosciences Brucellosis Vaccines Product Portfolio Table 72. Hester Biosciences Recent Developments Table 73. Zoetis Company Information Table 74. Zoetis Business Overview Table 75. Zoetis Brucellosis Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 76. Zoetis Brucellosis Vaccines Product Portfolio Table 77. Zoetis Recent Developments Table 78. Onderstepoort Biological Company Information Table 79. Onderstepoort Biological Business Overview Table 80. Onderstepoort Biological Brucellosis Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 81. Onderstepoort Biological Brucellosis Vaccines Product Portfolio Table 82. Onderstepoort Biological Recent Developments Table 83. Instituto Rosenbusch Company Information Table 84. Instituto Rosenbusch Business Overview Table 85. Instituto Rosenbusch Brucellosis Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 86. Instituto Rosenbusch Brucellosis Vaccines Product Portfolio Table 87. Instituto Rosenbusch Recent Developments Table 88. Ceva Sante Animale Company Information Table 89. Ceva Sante Animale Business Overview Table 90. Ceva Sante Animale Brucellosis Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 91. Ceva Sante Animale Brucellosis Vaccines Product Portfolio Table 92. Ceva Sante Animale Recent Developments Table 93. Calier & Biologicos Laverlam Company Information Table 94. Calier & Biologicos Laverlam Business Overview Table 95. Calier & Biologicos Laverlam Brucellosis Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 96. Calier & Biologicos Laverlam Brucellosis Vaccines Product Portfolio Table 97. Calier & Biologicos Laverlam Recent Developments Table 98. Biovet Company Information Table 99. Biovet Business Overview Table 100. Biovet Brucellosis Vaccines Sales (M Doses), Revenue (US$ Million), Price (USD/K Doses) and Gross Margin (2021-2026) Table 101. Biovet Brucellosis Vaccines Product Portfolio Table 102. Biovet Recent Developments Table 103. Global Brucellosis Vaccines Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 104. Global Brucellosis Vaccines Sales by Region (2021-2026) & (M Doses) Table 105. Global Brucellosis Vaccines Sales Market Share by Region (2021-2026) Table 106. Global Brucellosis Vaccines Sales by Region (2027-2032) & (M Doses) Table 107. Global Brucellosis Vaccines Sales Market Share by Region (2027-2032) Table 108. Global Brucellosis Vaccines Revenue by Region (2021-2026) & (US$ Million) Table 109. Global Brucellosis Vaccines Revenue Market Share by Region (2021-2026) Table 110. Global Brucellosis Vaccines Revenue by Region (2027-2032) & (US$ Million) Table 111. Global Brucellosis Vaccines Revenue Market Share by Region (2027-2032) Table 112. North America Brucellosis Vaccines Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. North America Brucellosis Vaccines Sales by Country (2021-2026) & (M Doses) Table 114. North America Brucellosis Vaccines Sales by Country (2027-2032) & (M Doses) Table 115. North America Brucellosis Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 116. North America Brucellosis Vaccines Revenue by Country (2027-2032) & (US$ Million) Table 117. Europe Brucellosis Vaccines Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Europe Brucellosis Vaccines Sales by Country (2021-2026) & (M Doses) Table 119. Europe Brucellosis Vaccines Sales by Country (2027-2032) & (M Doses) Table 120. Europe Brucellosis Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 121. Europe Brucellosis Vaccines Revenue by Country (2027-2032) & (US$ Million) Table 122. Asia Pacific Brucellosis Vaccines Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Asia Pacific Brucellosis Vaccines Sales by Country (2021-2026) & (M Doses) Table 124. Asia Pacific Brucellosis Vaccines Sales by Country (2027-2032) & (M Doses) Table 125. Asia Pacific Brucellosis Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 126. Asia Pacific Brucellosis Vaccines Revenue by Country (2027-2032) & (US$ Million) Table 127. South America Brucellosis Vaccines Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. South America Brucellosis Vaccines Sales by Country (2021-2026) & (M Doses) Table 129. South America Brucellosis Vaccines Sales by Country (2027-2032) & (M Doses) Table 130. South America Brucellosis Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 131. South America Brucellosis Vaccines Revenue by Country (2027-2032) & (US$ Million) Table 132. Middle East and Africa Brucellosis Vaccines Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Middle East and Africa Brucellosis Vaccines Sales by Country (2021-2026) & (M Doses) Table 134. Middle East and Africa Brucellosis Vaccines Sales by Country (2027-2032) & (M Doses) Table 135. Middle East and Africa Brucellosis Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 136. Middle East and Africa Brucellosis Vaccines Revenue by Country (2027-2032) & (US$ Million) Table 137. Global Brucellosis Vaccines Sales by Type (2021-2026) & (M Doses) Table 138. Global Brucellosis Vaccines Sales by Type (2027-2032) & (M Doses) Table 139. Global Brucellosis Vaccines Sales Market Share by Type (2021-2026) Table 140. Global Brucellosis Vaccines Sales Market Share by Type (2027-2032) Table 141. Global Brucellosis Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 142. Global Brucellosis Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 143. Global Brucellosis Vaccines Revenue Market Share by Type (2021-2026) Table 144. Global Brucellosis Vaccines Revenue Market Share by Type (2027-2032) Table 145. Global Brucellosis Vaccines Price by Type (2021-2026) & (USD/K Doses) Table 146. Global Brucellosis Vaccines Price by Type (2027-2032) & (USD/K Doses) Table 147. Global Brucellosis Vaccines Sales by Application (2021-2026) & (M Doses) Table 148. Global Brucellosis Vaccines Sales by Application (2027-2032) & (M Doses) Table 149. Global Brucellosis Vaccines Sales Market Share by Application (2021-2026) Table 150. Global Brucellosis Vaccines Sales Market Share by Application (2027-2032) Table 151. Global Brucellosis Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 152. Global Brucellosis Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 153. Global Brucellosis Vaccines Revenue Market Share by Application (2021-2026) Table 154. Global Brucellosis Vaccines Revenue Market Share by Application (2027-2032) Table 155. Global Brucellosis Vaccines Price by Application (2021-2026) & (USD/K Doses) Table 156. Global Brucellosis Vaccines Price by Application (2027-2032) & (USD/K Doses) Table 157. Key Raw Materials Table 158. Raw Materials Key Suppliers Table 159. Brucellosis Vaccines Distributors List Table 160. Brucellosis Vaccines Customers List Table 161. Brucellosis Vaccines Industry Trends Table 162. Brucellosis Vaccines Industry Drivers Table 163. Brucellosis Vaccines Industry Restraints Table 164. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Brucellosis Vaccines Product Image Figure 5. Global Brucellosis Vaccines Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Brucellosis Vaccines Market Size (2021-2032) & (US$ Million) Figure 7. Global Brucellosis Vaccines Sales (2021-2032) & (M Doses) Figure 8. Global Brucellosis Vaccines Average Price (USD/K Doses) & (2021-2032) Figure 9. S19 Vaccine Product Image Figure 10. RB51 Vaccine Strain Product Image Figure 11. Cattle Product Image Figure 12. Sheep Product Image Figure 13. Others Product Image Figure 14. Global Brucellosis Vaccines Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Brucellosis Vaccines, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Brucellosis Vaccines Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Brucellosis Vaccines Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Brucellosis Vaccines Sales by Region in 2025 Figure 20. Global Brucellosis Vaccines Revenue by Region in 2025 Figure 21. North America Brucellosis Vaccines Market Size by Country in 2025 Figure 22. North America Brucellosis Vaccines Sales Market Share by Country (2021-2032) Figure 23. North America Brucellosis Vaccines Revenue Market Share by Country (2021-2032) Figure 24. United States Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Brucellosis Vaccines Market Size by Country in 2025 Figure 28. Europe Brucellosis Vaccines Sales Market Share by Country (2021-2032) Figure 29. Europe Brucellosis Vaccines Revenue Market Share by Country (2021-2032) Figure 30. Germany Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Brucellosis Vaccines Market Size by Country in 2025 Figure 41. Asia Pacific Brucellosis Vaccines Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Brucellosis Vaccines Revenue Market Share by Country (2021-2032) Figure 43. China Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Brucellosis Vaccines Market Size by Country in 2025 Figure 52. South America Brucellosis Vaccines Sales Market Share by Country (2021-2032) Figure 53. South America Brucellosis Vaccines Revenue Market Share by Country (2021-2032) Figure 54. Brazil Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Colombia Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Middle East and Africa Brucellosis Vaccines Market Size by Country in 2025 Figure 59. Middle East and Africa Brucellosis Vaccines Sales Market Share by Country (2021-2032) Figure 60. Middle East and Africa Brucellosis Vaccines Revenue Market Share by Country (2021-2032) Figure 61. Egypt Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. South Africa Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Israel Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Türkiye Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. GCC Countries Brucellosis Vaccines Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Global Brucellosis Vaccines Sales Market Share by Type (2021-2032) Figure 67. Global Brucellosis Vaccines Revenue Market Share by Type (2021-2032) Figure 68. Global Brucellosis Vaccines Price (USD/K Doses) by Type (2021-2032) Figure 69. Global Brucellosis Vaccines Sales Market Share by Application (2021-2032) Figure 70. Global Brucellosis Vaccines Revenue Market Share by Application (2021-2032) Figure 71. Global Brucellosis Vaccines Price (USD/K Doses) by Application (2021-2032) Figure 72. Brucellosis Vaccines Value Chain Figure 73. Brucellosis Vaccines Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Brucellosis Vaccines Industry Opportunities and Challenges

Scope & coverage.

Types
  • S19 Vaccine
  • RB51 Vaccine Strain
Applications
  • Cattle
  • Sheep
  • Others
Companies covered
  • Jinyu
  • Colorado Serum
  • Boehringer Ingelheim
  • Biogenesis-Bago
  • Vetal Company
  • CZ Veterinaria
  • SYVA Laboratorios
  • Indian Immunologicals
  • Qilu
  • Tecnovax
  • Hester Biosciences
  • Zoetis
  • Onderstepoort Biological
  • Instituto Rosenbusch
  • Ceva Sante Animale
  • Calier & Biologicos Laverlam
  • Biovet

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Brucellosis Vaccines Market Size (2021-2032)
  4. 2.2.2 Global Brucellosis Vaccines Sales (2021-2032)
  5. 2.2.3 Global Brucellosis Vaccines Market Average Price (2021-2032)
  6. 2.3 Brucellosis Vaccines by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 S19 Vaccine
  9. 2.3.3 RB51 Vaccine Strain
  10. 2.4 Brucellosis Vaccines by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Cattle
  13. 2.4.3 Sheep
  14. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Brucellosis Vaccines Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Brucellosis Vaccines Sales (M Doses) of Manufacturers (2021-2026)
  3. 3.3 Global Brucellosis Vaccines Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Brucellosis Vaccines Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Brucellosis Vaccines Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Brucellosis Vaccines, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Brucellosis Vaccines, Product Type & Application
  8. 3.8 Global Manufacturers of Brucellosis Vaccines, Established Date
  9. 3.9 Global Brucellosis Vaccines Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Jinyu
  2. 4.1.1 Jinyu Company Information
  3. 4.1.2 Jinyu Business Overview
  4. 4.1.3 Jinyu Brucellosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Jinyu Brucellosis Vaccines Product Portfolio
  6. 4.1.5 Jinyu Recent Developments
  7. 4.2 Colorado Serum
  8. 4.2.1 Colorado Serum Company Information
  9. 4.2.2 Colorado Serum Business Overview
  10. 4.2.3 Colorado Serum Brucellosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Colorado Serum Brucellosis Vaccines Product Portfolio
  12. 4.2.5 Colorado Serum Recent Developments
  13. 4.3 Boehringer Ingelheim
  14. 4.3.1 Boehringer Ingelheim Company Information
  15. 4.3.2 Boehringer Ingelheim Business Overview
  16. 4.3.3 Boehringer Ingelheim Brucellosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Boehringer Ingelheim Brucellosis Vaccines Product Portfolio
  18. 4.3.5 Boehringer Ingelheim Recent Developments
  19. 4.4 Biogenesis-Bago
  20. 4.4.1 Biogenesis-Bago Company Information
  21. 4.4.2 Biogenesis-Bago Business Overview
  22. 4.4.3 Biogenesis-Bago Brucellosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Biogenesis-Bago Brucellosis Vaccines Product Portfolio
  24. 4.4.5 Biogenesis-Bago Recent Developments
  25. 4.5 Vetal Company
  26. 4.5.1 Vetal Company Company Information
  27. 4.5.2 Vetal Company Business Overview
  28. 4.5.3 Vetal Company Brucellosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Vetal Company Brucellosis Vaccines Product Portfolio
  30. 4.5.5 Vetal Company Recent Developments
  31. 4.6 CZ Veterinaria
  32. 4.6.1 CZ Veterinaria Company Information
  33. 4.6.2 CZ Veterinaria Business Overview
  34. 4.6.3 CZ Veterinaria Brucellosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 CZ Veterinaria Brucellosis Vaccines Product Portfolio
  36. 4.6.5 CZ Veterinaria Recent Developments
  37. 4.7 SYVA Laboratorios
  38. 4.7.1 SYVA Laboratorios Company Information
  39. 4.7.2 SYVA Laboratorios Business Overview
  40. 4.7.3 SYVA Laboratorios Brucellosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 SYVA Laboratorios Brucellosis Vaccines Product Portfolio
  42. 4.7.5 SYVA Laboratorios Recent Developments
  43. 4.8 Indian Immunologicals
  44. 4.8.1 Indian Immunologicals Company Information
  45. 4.8.2 Indian Immunologicals Business Overview
  46. 4.8.3 Indian Immunologicals Brucellosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Indian Immunologicals Brucellosis Vaccines Product Portfolio
  48. 4.8.5 Indian Immunologicals Recent Developments
  49. 4.9 Qilu
  50. 4.9.1 Qilu Company Information
  51. 4.9.2 Qilu Business Overview
  52. 4.9.3 Qilu Brucellosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Qilu Brucellosis Vaccines Product Portfolio
  54. 4.9.5 Qilu Recent Developments
  55. 4.10 Tecnovax
  56. 4.10.1 Tecnovax Company Information
  57. 4.10.2 Tecnovax Business Overview
  58. 4.10.3 Tecnovax Brucellosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Tecnovax Brucellosis Vaccines Product Portfolio
  60. 4.10.5 Tecnovax Recent Developments
  61. 4.11 Hester Biosciences
  62. 4.11.1 Hester Biosciences Company Information
  63. 4.11.2 Hester Biosciences Business Overview
  64. 4.11.3 Hester Biosciences Brucellosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Hester Biosciences Brucellosis Vaccines Product Portfolio
  66. 4.11.5 Hester Biosciences Recent Developments
  67. 4.12 Zoetis
  68. 4.12.1 Zoetis Company Information
  69. 4.12.2 Zoetis Business Overview
  70. 4.12.3 Zoetis Brucellosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Zoetis Brucellosis Vaccines Product Portfolio
  72. 4.12.5 Zoetis Recent Developments
  73. 4.13 Onderstepoort Biological
  74. 4.13.1 Onderstepoort Biological Company Information
  75. 4.13.2 Onderstepoort Biological Business Overview
  76. 4.13.3 Onderstepoort Biological Brucellosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Onderstepoort Biological Brucellosis Vaccines Product Portfolio
  78. 4.13.5 Onderstepoort Biological Recent Developments
  79. 4.14 Instituto Rosenbusch
  80. 4.14.1 Instituto Rosenbusch Company Information
  81. 4.14.2 Instituto Rosenbusch Business Overview
  82. 4.14.3 Instituto Rosenbusch Brucellosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Instituto Rosenbusch Brucellosis Vaccines Product Portfolio
  84. 4.14.5 Instituto Rosenbusch Recent Developments
  85. 4.15 Ceva Sante Animale
  86. 4.15.1 Ceva Sante Animale Company Information
  87. 4.15.2 Ceva Sante Animale Business Overview
  88. 4.15.3 Ceva Sante Animale Brucellosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Ceva Sante Animale Brucellosis Vaccines Product Portfolio
  90. 4.15.5 Ceva Sante Animale Recent Developments
  91. 4.16 Calier & Biologicos Laverlam
  92. 4.16.1 Calier & Biologicos Laverlam Company Information
  93. 4.16.2 Calier & Biologicos Laverlam Business Overview
  94. 4.16.3 Calier & Biologicos Laverlam Brucellosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Calier & Biologicos Laverlam Brucellosis Vaccines Product Portfolio
  96. 4.16.5 Calier & Biologicos Laverlam Recent Developments
  97. 4.17 Biovet
  98. 4.17.1 Biovet Company Information
  99. 4.17.2 Biovet Business Overview
  100. 4.17.3 Biovet Brucellosis Vaccines Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Biovet Brucellosis Vaccines Product Portfolio
  102. 4.17.5 Biovet Recent Developments
5 Global Brucellosis Vaccines Market Scenario by Region
  1. 5.1 Global Brucellosis Vaccines Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Brucellosis Vaccines Sales by Region: 2021-2032
  3. 5.2.1 Global Brucellosis Vaccines Sales by Region: 2021-2026
  4. 5.2.2 Global Brucellosis Vaccines Sales by Region: 2027-2032
  5. 5.3 Global Brucellosis Vaccines Revenue by Region: 2021-2032
  6. 5.3.1 Global Brucellosis Vaccines Revenue by Region: 2021-2026
  7. 5.3.2 Global Brucellosis Vaccines Revenue by Region: 2027-2032
  8. 5.4 North America Brucellosis Vaccines Market Facts & Figures by Country
  9. 5.4.1 North America Brucellosis Vaccines Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Brucellosis Vaccines Sales by Country (2021-2032)
  11. 5.4.3 North America Brucellosis Vaccines Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Brucellosis Vaccines Market Facts & Figures by Country
  16. 5.5.1 Europe Brucellosis Vaccines Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Brucellosis Vaccines Sales by Country (2021-2032)
  18. 5.5.3 Europe Brucellosis Vaccines Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Brucellosis Vaccines Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Brucellosis Vaccines Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Brucellosis Vaccines Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Brucellosis Vaccines Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Brucellosis Vaccines Market Facts & Figures by Country
  41. 5.7.1 South America Brucellosis Vaccines Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Brucellosis Vaccines Sales by Country (2021-2032)
  43. 5.7.3 South America Brucellosis Vaccines Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa Brucellosis Vaccines Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa Brucellosis Vaccines Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa Brucellosis Vaccines Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa Brucellosis Vaccines Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Brucellosis Vaccines Sales by Type (2021-2032)
  2. 6.1.1 Global Brucellosis Vaccines Sales by Type (2021-2032) & (M Doses)
  3. 6.1.2 Global Brucellosis Vaccines Sales Market Share by Type (2021-2032)
  4. 6.2 Global Brucellosis Vaccines Revenue by Type (2021-2032)
  5. 6.2.1 Global Brucellosis Vaccines Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Brucellosis Vaccines Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Brucellosis Vaccines Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Brucellosis Vaccines Sales by Application (2021-2032)
  2. 7.1.1 Global Brucellosis Vaccines Sales by Application (2021-2032) & (M Doses)
  3. 7.1.2 Global Brucellosis Vaccines Sales Market Share by Application (2021-2032)
  4. 7.2 Global Brucellosis Vaccines Revenue by Application (2021-2032)
  5. 7.2.1 Global Brucellosis Vaccines Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Brucellosis Vaccines Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Brucellosis Vaccines Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Brucellosis Vaccines Value Chain Analysis
  2. 8.1.1 Brucellosis Vaccines Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Brucellosis Vaccines Production Mode & Process
  5. 8.2 Brucellosis Vaccines Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Brucellosis Vaccines Distributors
  8. 8.2.3 Brucellosis Vaccines Customers
9 Global Brucellosis Vaccines Analyzing Market Dynamics
  1. 9.1 Brucellosis Vaccines Industry Trends
  2. 9.2 Brucellosis Vaccines Industry Drivers
  3. 9.3 Brucellosis Vaccines Industry Opportunities and Challenges
  4. 9.4 Brucellosis Vaccines Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst